Clinical Research
Retina Associates of Utah is proud to partner with a variety of pharmaceutical companies to bring patients the newest innovations in retinal disease treatment. Currently, we are conducting nine (9) clinical studies with others in our research pipeline. From providing important safety and efficacy data for FDA approved Lucentis (monospecific anti-VEGF antibody), Susvimo (port delivery system aka implant) and Vabysmo (the first bispecific antiVEGF antibody) to safely administering other novel therapies including gene therapy, RAU strives to serve patients in Utah with innovative treatments for wet and dry macular degeneration, diabetic macular edema, retinal vein occlusions, and more.
To learn more details about our clinical studies or to inquire about how to participate, please contact our research department (801) 312-2070.
Current Clinical Studies
Currently Enrolling
Regenxbio Gene Therapy for Wet Macular Degeneration;
ISIS subcutaneous injection for Dry Macular Degeneration
Closed Enrollment (In Active Follow Up)
Port Delivery System with Lucentis (Susvimo) for Wet Macular Degeneration
Port Delivery System with Lucentis (Susvimo) for Diabetic Macular Edema; close enrollment, in active follow up
Faricimab (Vabysmo) intravitreal injection for Diabetic Macular Edema
Faricimab (Vabysmo) intravitreal injection for Wet Macular Degeneration
Gather2 intravitreal injection for Dry Macular Degeneration;
Faricimab (Vabysmo) intravitreal injection for branch retinal vein occusion
Faricimab (Vabysmo) intravitreal injection for central retinal vein occlusion
Studies in Our Pipleine
Gene Therapy for Wet Macular Degeneration
Port Delivery System with Lucentis (Susvimo) for Wet Macular Degeneration
Anti-VEGF intravitreal injection for Wet Macular Degeneration